Kinase inhibitors: the road ahead. (Q52653219)

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The regulation of protein function by multisite phosphorylation--a 25 year update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The protein kinase complement of the human genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The ins and outs of selective kinase inhibitor development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Protein kinase inhibitors as a therapeutic modality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The (un)targeted cancer kinome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

New frontiers in kinases: special issue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Tracking cancer drugs in living cells by thermal profiling of the proteome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The basal transcription machinery as a target for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Transcriptional Addiction in Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Dysregulation of the basal RNA polymerase transcription apparatus in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Super-enhancers in the control of cell identity and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

31 March 2020

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Selective inhibition of tumor oncogenes by disruption of super-enhancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The half-life of c-myc mRNA in growing and serum-stimulated cells: influence of the coding and 3' untranslated regions and role of ribosome translocation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Strategically targeting MYC in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Directly targeting transcriptional dysregulation in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA polymerase II CTD kinase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The CDK-activating kinase Cdk7: taking yes for an answer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

RNA polymerase II transcription elongation control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Mediator kinase inhibition further activates super-enhancer-associated genes in AML

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Overview of CDK9 as a target in cancer research.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Microenvironmental regulation of tumor progression and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Cancer Immunology and Immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Immunobiology of the TAM receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

AXL and acquired resistance to EGFR inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Mechanisms of drug resistance in kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Combining immunotherapy and targeted therapies in cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Combination cancer immunotherapy and new immunomodulatory targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

PI3Kγ is a molecular switch that controls immune suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

EGFR TKI combination with immunotherapy in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

CDK4/6 inhibition triggers anti-tumour immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Global survey of the immunomodulatory potential of common drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Translational value of mouse models in oncology drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Toll-like receptor signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Mechanisms and consequences of Jak-STAT signaling in the immune system.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Kinase inhibitors in the treatment of immune-mediated disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Targeting protein kinases for the development of anti-inflammatory drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Kinase inhibitors and monoclonal antibodies in oncology: clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Bruton's tyrosine kinase (BTK) inhibitors in clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Toll-like receptor (TLR) response tolerance: a key physiological "damage limitation" effect and an important potential opportunity for therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Drug repositioning for Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Animal models of CNS disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Screening out irrelevant cell-based models of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Allosteric inhibition of the IRE1α RNase preserves cell viability and function during endoplasmic reticulum stress.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

On the mechanism of sensing unfolded protein in the endoplasmic reticulum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The crystal structure of human IRE1 luminal domain reveals a conserved dimerization interface required for activation of the unfolded protein response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Signaling cell death from the endoplasmic reticulum stress response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

An integrated stress response regulates amino acid metabolism and resistance to oxidative stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (P

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Dual leucine zipper kinase-dependent PERK activation contributes to neuronal degeneration following insult.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Mechanisms of age-related macular degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Conjugate adaptation of smooth pursuit during monocular viewing in strabismic monkeys with exotropia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Lectin microarray profiling and relative quantification of glycome associated with proteins of neonatal wt and rd1 mice retinae

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Evolution of a New Class of VEGFR-2 Inhibitors from Scaffold Morphing and Redesign

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Neutralization of vascular endothelial growth factor antiangiogenic isoforms is more effective than treatment with proangiogenic isoforms in stimulating vascular development and follicle progression in the perinatal rat ovary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Kinases in synaptic development and neurological diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Molecular neurobiology of mTOR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Targeting LRRK2 in Parkinson's disease: an update on recent developments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Plasmodium kinases as targets for new-generation antimalarials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Targeting Plasmodium PI(4)K to eliminate malaria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Chemical interrogation of the malaria kinome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Sphingosine kinase 1 in viral infections.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Could pharmacological curtailment of the RhoA/Rho-kinase pathway reverse the endothelial barrier dysfunction associated with Ebola virus infection?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Protein kinases as antibacterial targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Mycobacterium tuberculosis Serine/Threonine Protein Kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Imatinib resistance in CML.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Measuring and interpreting the selectivity of protein kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Rational drug design: Tuning kinase inhibitor residence time.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Targeting cancer with small molecule kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

EML4-ALK fusions: propelling cancer but creating exploitable chaperone dependence.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Selective inhibition of the kinase DYRK1A by targeting its folding process

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Catalytic in vivo protein knockdown by small-molecule PROTACs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Induced protein degradation: an emerging drug discovery paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Small-Molecule PROTACS: New Approaches to Protein Degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Degradation of Akt using protein-catalyzed capture agents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Pharmacological targeting of the pseudokinase Her3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Structural basis of PROTAC cooperative recognition for selective protein degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Protein Degradation via CRL4CRBN Ubiquitin Ligase: Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Proteasome Activation by Small Molecules.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Developing irreversible inhibitors of the protein kinase cysteinome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Targeting the Protein Kinases Cysteinome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Irreversible enzyme inhibition kinetics and drug-drug interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Metabolically Labile Fumarate Esters Impart Kinetic Selectivity to Irreversible Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Prolonged and tunable residence time using reversible covalent kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Covalent docking of large libraries for the discovery of chemical probes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Proteome-wide covalent ligand discovery in native biological systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Identification and Characterization of an Irreversible Inhibitor of CDK2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Redox-based reagents for chemoselective methionine bioconjugation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Role of LRRK2 kinase dysfunction in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based D

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

ERK5 and Cell Proliferation: Nuclear Localization Is What Matters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Oncogenic signaling of MEK5-ERK5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

ERK5 kinase activity is dispensable for cellular immune response and proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

High-throughput kinase profiling as a platform for drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Activity-based protein profiling for biochemical pathway discovery in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

In situ kinase profiling reveals functionally relevant properties of native kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Optimized chemical proteomics assay for kinase inhibitor profiling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Kinobead and Single-Shot LC-MS Profiling Identifies Selective PKD Inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Non-kinase targets of protein kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Enzyme inhibitor discovery by activity-based protein profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Activity-based protein profiling: recent advances in probe development and applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Chemistry-based functional proteomics for drug target deconvolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Thermal proteome profiling monitors ligand interactions with cellular membrane proteins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

KLIFS: a structural kinase-ligand interaction database

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

GPCRdb: an information system for G protein-coupled receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

3D-e-Chem-VM: Structural Cheminformatics Research Infrastructure in a Freely Available Virtual Machine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Profiling Prediction of Kinase Inhibitors: Toward the Virtual Assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Progress towards a public chemogenomic set for protein kinases and a call for contributions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The target landscape of clinical kinase drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Computational methods in drug discovery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Thermodynamic contributions of the ordered water molecule in HIV-1 protease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Quantifying the entropy of binding for water molecules in protein cavities by computing correlations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Computing the thermodynamic contributions of interfacial water

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Understanding kinase selectivity through energetic analysis of binding site waters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Role of the active-site solvent in the thermodynamics of factor Xa ligand binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Binding free-energy calculation is a powerful tool for drug optimization: calculation and measurement of binding free energy for 7-azaindole derivatives to glycogen synthase kinase-3β

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Explaining why Gleevec is a specific and potent inhibitor of Abl kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The Effect of Conformational Flexibility on Binding Free Energy Estimation between Kinases and Their Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Dynamic undocking and the quasi-bound state as tools for drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Receptor tyrosine kinases and targeted cancer therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Neuroprotective Mechanisms Mediated by CDK5 Inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Sulfonyl fluorides as privileged warheads in chemical biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Vinyl sulfone: a versatile function for simple bioconjugation and immobilization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Redox-based probes as tools to monitor oxidized protein tyrosine phosphatases in living cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Redox-based probes for protein tyrosine phosphatases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

Isoform-specific regulation of Akt by PDGF-induced reactive oxygen species

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

7 January 2021

inferred from DOI database lookup

Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

7 January 2021

inferred from DOI database lookup

Future therapies of wet age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.21

7 January 2021

inferred from DOI database lookup

Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists

1 reference

12 December 2020

Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment

1 reference

12 December 2020

Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases

1 reference

12 December 2020

Taking PI3Kδ and PI3Kγ one step ahead: dual active PI3Kδ/γ inhibitors for the treatment of immune-mediated inflammatory diseases

1 reference

12 December 2020

EGFR mutant lung cancer

1 reference

12 December 2020

DYRK1A kinase inhibitors with emphasis on cancer

1 reference

12 December 2020

Selective Mycobacterium tuberculosis Shikimate Kinase Inhibitors as Potential Antibacterials

1 reference

12 December 2020

Protein-kinase inhibitors: A new treatment pathway for autoimmune and inflammatory diseases?

1 reference

12 December 2020

Emerging Roles for RIPK1 and RIPK3 in Pathogen-Induced Cell Death and Host Immunity

1 reference

12 December 2020

Propelling Immunotherapy Combinations Into the Clinic

1 reference

12 December 2020

A Perspective on the Kinetics of Covalent and Irreversible Inhibition

1 reference

12 December 2020